Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma

NCT01882803 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT01882803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01882803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma
Lead sponsor
SecuraBio
Phase
Phase 2
Overall status
Completed
Start date
June 17, 2013
Completion date
November 18, 2020
Enrollment
129 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

indolent non-hodgkin lymphoma